Belite Bio, Inc
NASDAQ:BLTEBiotechnology
+$0.46 today
- Market cap
- $6.29B
- Beta
- -1.24
- P/E (TTM)
- -65.9
- EPS (TTM)
- -$2.26
Volume 0.09M
Average 0.17M
BLTE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Belite Bio, IncNASDAQ: BLTE
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q3 FY2026 selling, general & admin of $21.43M rose 68.6% year over year, behind the +131.9% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 28.4% from the prior quarter. Over 3 fiscal years it compounded at +114.2% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +286.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $21.43M+28.4% QoQ
- Last fiscal yearDec 2025
- $38.83M+286.1% YoY
- LTMSep 2026
- $68.6M+131.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +68.6% | -100.0% | -168.6 pp |
| 1 year | +286.1% | -100.0% | -386.1 pp |
| 3-year CAGR | +114.2% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 38.83M USD
- Year-over-year change
- +286.1%
- 4-year CAGR
- +101.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 38.83M | +286.1% |
| FY2024 | 2024-12-31 | 10.06M | +47.4% |
| FY2023 | 2023-12-31 | 6.82M | +72.7% |
| FY2022 | 2022-12-31 | 3.95M | +66.2% |
| FY2021 | 2021-12-31 | 2.38M | — |
Selling, General & Admin vs competitors
How BLTE compares with its peers on the latest reported figures
- BLTE's LTM Sep 2026 selling, general & admin of $68.6M is the highest of the 6 companies compared; the peer median is $29.24M.
- Its year-over-year change of +131.9% is the highest of 6, against a peer median of +1.3%.
- Over three fiscal years its annual growth of +114.2% compares with a peer median of -5.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLTEBelite Bio, Inc | LTM Sep 2026 | $68.6M | +131.9% | +114.2% | — |
| LTM Mar 2026 | $53.04M | +1.3% | -5.0% | 696.5% | |
| LTM Sep 2026 | $42.74M | -6.8% | -6.1% | — | |
| LTM Mar 2026 | $29.24M | +9.4% | -8.0% | 654.9% | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $21.57M | +8.6% | +44.6% | 180.0% |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $15.32M | -41.8% | +90.0% | — |
| Peer median (excluding BLTE) | $29.24M | +1.3% | -5.0% | 654.9% | |
Competitors are the stored peer set for BLTE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 7.42M | 8.87M | 24.84M | 29.94M | 45.38M |
| Selling, General & Admin | 2.38M | 3.95M | 6.82M | 10.06M | 38.83M |
| Operating Expenses | 9.8M | 12.82M | 31.67M | 40M | 84.21M |
| Depreciation & Amortization | 30K | 198K | 399K | 449K | 464K |
| EBITDA | (9.64M) | (12.43M) | (31.2M) | (35.67M) | (77.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (9.8M) | (12.82M) | (31.67M) | (40M) | (84.21M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 5K | 23K | 74K | 3.74M | 0 |
| Interest Expense | 0 | 16K | 25K | 20K | 0 |
| Other Income / Expenses | 131K | 173K | 45K | 3.86M | 6.6M |
| Income Before Tax | (9.67M) | (12.65M) | (31.62M) | (36.14M) | (77.61M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 9K | 6K | 0 |
| Net Income | (9.67M) | (12.65M) | (31.63M) | (36.14M) | (77.61M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| EPS (Diluted) | (0.40) | (0.63) | (1.19) | (1.18) | (2.31) |
| Weighted Avg Shares | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
| Weighted Avg Shares (Diluted) | 24.1M | 19.98M | 26.59M | 30.54M | 33.54M |
Belite Bio, Inc
NASDAQ:BLTE
Intrinsic Alpha fair value
Locked
Current Price
$156.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.